Summary & Overview
HCPCS L8604: Dextranomer/Hyaluronic Acid Urethral Bulking Agent, 1 ml
HCPCS Level II code L8604 identifies a 1 ml injectable bulking agent composed of dextranomer/hyaluronic acid copolymer for use in the urinary tract and includes shipping and necessary supplies. The code captures the device/implant component of urethral bulking procedures used to manage urinary incontinence and related urinary tract conditions. Nationally, this code matters because it standardizes reporting for an implantable injectable product that is an alternative to surgical incontinence repairs and helps track device utilization and supply billing.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find benchmarks for code use and coverage patterns, context on clinical applications of urethral bulking agents, and summaries of policy considerations affecting device billing and supply reimbursement. The publication also outlines common modifiers observed on claims and notes where data was not provided in the input.
This summary equips billing professionals, urology clinicians, and policy analysts with a concise reference to the clinical purpose of L8604, typical places of service, and the payer landscape to inform coding, claims submission, and administrative planning.
Billing Code Overview
HCPCS Level II code L8604 describes an injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies. This product is used as an injectable urethral bulking agent intended to augment tissue in the urinary tract to treat urinary incontinence or related urinary tract insufficiency.
Service type: Injectable bulking agent administration
Typical site of service: Outpatient clinic or ambulatory surgical center, including urology offices where minimally invasive injections are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult experiencing symptomatic stress urinary incontinence after vaginal childbirth or pelvic surgery. The patient reports urine leakage with exertion such as coughing, sneezing, or exercising, refractory to pelvic floor physical therapy and behavioral measures. Evaluation by a urologist or urogynecologist includes history, physical exam with cough stress test, post-void residual measurement, urinalysis to exclude infection, and consideration of cystoscopic evaluation. After shared decision-making, the clinician performs endoscopic periurethral injection of a bulking agent, L8604 (dextranomer/hyaluronic acid copolymer implant, 1 ml), typically in an outpatient ambulatory surgery center or hospital outpatient department under local, regional, or monitored anesthesia care. The workflow includes informed consent, sterile preparation, cystoscopic guidance to the periurethral tissues, injection of the appropriate volume of L8604 to coapt the urethral lumen, post-procedure voiding trial assessment, and discharge with activity and follow-up instructions. Common immediate documentation includes indication, volume injected, lot number and expiration of the implant, anesthesia type, any intra-procedural complications, and post-void residual measurement prior to discharge.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |